Can an early weight management program (WMP) prevent olanzapine (OLZ)-induced disturbances in body weight, blood glucose and lipid metabolism? Twenty-four- and 48-week results from a 6-month randomized trial. (April 2014)

• Record Type: Journal Article
• Authors: Cordes, Joachim; Thünker, Johanna; Regenbrecht, Gunnar; Zielasek, Jürgen; Correll, Christoph U.; Schmidt-Kraepelin, Christian; Lange-Asschenfeldt, Christian; Agelink, Marcus W.; Kahl, Kai G.; Gaebel, Wolfgang; Klimke, Ansgar; Hauner, Hans
• Is Part Of: World journal of biological psychiatry. Volume 15:Number 3(2014)
• Page Start: 229
• Page End: 241
• Publication Date: 2014-04
• Subjects: Biological psychiatry -- Periodicals; Biological Psychiatry -- Periodicals; 616.89
• DOI: 10.3109/15622975.2011.592546
• Languages: English
• ISSNs: 1562-2975

Abstract

<abstract> <title>Abstract</title> <p> <italic>Objectives</italic>. This study was designed to investigate whether a preventive weight management program (WMP) reduces weight gain during olanzapine (OLZ) treatment. Moreover, we examined the effects of intervention on metabolic parameters. <italic>Methods.</italic> Patients (<italic>N</italic> = 100) with schizophrenia or schizoaffective disorder (DSM-IV) who had commenced treatment with OLZ were recruited. Following a run-in period of 4 weeks, 74 patients who had gained at least 1.5 kg body weight were randomized to receive either 12 bi-weekly WMP sessions (prevention group (PG), <italic>n</italic> = 36), or usual care (control group (CG), <italic>n</italic> = 38). Anthropometric and metabolic parameters were assessed after the 24-week intervention phase and a 24-week follow-up. <italic>Results</italic>. Forty-two percent of 74 participants (PG: 36.1%, CG: 47.4%) finished the 24-week intervention phase while 34% of them (PG: 30.6%, CG: 36.8%) completed the 48-week study. There was no significant difference in weight gain between groups (PG: + 3.4 ± 4.2 kg vs. CG: + 4.5 ± 6.1 kg, <italic>P</italic> = 0.184) after 24 weeks. Nevertheless, PG showed a significantly smaller increase in waist circumference than CG (PG: + 4.6 ± 8.3 cm, CG: + 10.1 ± 7.3 cm, <italic>P</italic> = 0.019) after 48 weeks. Furthermore, PG showed a significantly smaller increase in fasting glucose (<italic>P</italic> = 0.031) and 2-h glucose after oral glucose load (<italic>P</italic> = 0.018) than CG. <italic>Conclusions</italic>. These results suggest that preventive WMP may reduce the risk of abdominal obesity and deterioration of glucose metabolism in OLZ-treated patients.</p> </abstract>